XUCHEN ZHANG
Medical Practice at Skyview Rd, Orange, CT
License number
Florida 122238
Issued Date
Nov 21, 2014
Effective Date
Nov 17, 2016
Expiration Date
Jan 31, 2017
Category
Health Care
Type
Medical Doctor
Address
Address
2
7 Skyview Rd, Orange, CT 06477
950 Campbell Ave, New Haven, CT 06520
950 Campbell Ave, New Haven, CT 06520
Phone
(203) 298-4568
Professional information
Xuchen Zhang, West Haven CT
Work:
Va Connecticut Healthcare Systemwest Haven Campus
950 Campbell Ave, West Haven, CT 06516
950 Campbell Ave, West Haven, CT 06516
Dr. Xuchen Zhang, West Haven CT - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology
Address:
950 Campbell Ave, West Haven 06516
(203) 932-5711 (Phone)
(203) 932-5711 (Phone)
Certifications:
Anatomic & Clinical Pathology, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Residency Hospital
SUNY Downstate
SUNY Downstate
Intranasal Delivery Of Nucleic Acid Molecules
US Patent:
2008031, Dec 25, 2008
Filed:
Jul 2, 2008
Appl. No.:
12/166926
Inventors:
Patty Lee - Guilford CT, US
Xuchen Zhang - Orange CT, US
Xuchen Zhang - Orange CT, US
International Classification:
A61K 31/7088, A61P 11/02
US Classification:
514 44
Abstract:
Aerosol delivery of nucleic acids to the lungs using viral vectors, polymers, surfactants, or excipients has been described. Compositions for intranasal administration are described that contain nucleic acids without viral or plasmid vectors and with little to no polymers, surfactants, or excipients. In one embodiment, the composition for intranasal delivery consists essentially of at least one nucleic acid and an aqueous solution. Suitable nucleic acids for intranasal delivery include, but are not limited to, dsDNA, dsRNA, ssDNA, ssRNA, short interfering RNA, micro-RNA, and antisense RNA Methods for treatment, diagnosis, or prevention of at least one symptom or manifestation of a lung disease are also described consisting of administration by intranasal delivery an effective amount of a composition containing a nucleic acid. The composition may be formulated as a liquid or aerosol or other acceptable formulation for intranasal administration.
Intranasal Delivery Of Nucleic Acid Molecules
US Patent:
2005026, Dec 1, 2005
Filed:
May 3, 2005
Appl. No.:
11/120370
Inventors:
Patty Lee - Guilford CT, US
Xuchen Zhang - Orange CT, US
Xuchen Zhang - Orange CT, US
International Classification:
A61K048/00, A61L009/04, A61K009/14
US Classification:
424046000, 514044000
Abstract:
Aerosol delivery of nucleic acids to the lungs using viral vectors, polymers, surfactants, or excipients has been described. Compositions for intranasal administration are described that contain nucleic acids without viral or plasmid vectors and with little to no polymers, surfactants, or excipients. In one embodiment, the composition for intranasal delivery consists essentially of at least one nucleic acid and an aqueous solution. Suitable nucleic acids for intranasal delivery include, but are not limited to, dsDNA, dsRNA, ssDNA, ssRNA, short interfering RNA, micro-RNA, and antisense RNA. Methods for treatment, diagnosis, or prevention of at least one symptom or manifestation of a lung disease are also described consisting of administration by intranasal delivery an effective amount of a composition containing a nucleic acid. The composition may be formulated as a liquid or aerosol or other acceptable formulation for intranasal administration.
Toll-Like Receptor 4 Deficiency And Downstream Effectors Cause Pulmonary Emphysema
US Patent:
2010008, Apr 8, 2010
Filed:
Sep 11, 2009
Appl. No.:
12/558308
Inventors:
Patty Lee - Guilford CT, US
Xuchen Zhang - Orange CT, US
Xuchen Zhang - Orange CT, US
International Classification:
A61K 39/395, C12Q 1/37, G01N 33/573, C12Q 1/68, A61K 31/7088
US Classification:
4241331, 435 23, 435 74, 435 6, 4241301, 4241411, 514 44 A, 514 44 R
Abstract:
The present invention provides compositions and methods for the detection, treatment, and prevention of emphysema/COPD. Compositions of the present invention comprise TLR4 activators, Nox3 inhibitors, and Cathepsin E inhibitors useful in the treatment or prevention of emphysema/COPD. Cathepsin E is a downstream effector of TLR4, wherein when cathepsin E is overexpressed in lung of an individual, the individual is at higher risk of developing emphysema/COPD. Cathepsin E is further identified as a biomarker useful in the identification of an individual with, or at-risk of developing emphysema/COPD.